FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938854921> ?p ?o ?g. }

• W2938854921 endingPage "e967" @default.
• W2938854921 startingPage "e960" @default.
• W2938854921 abstract "The optimal prognostic factors in patients with advanced cancer are not known, as a comparison of these is lacking. The aim of the present study was to determine the optimal prognostic factors by comparing validated factors.A multicenter, prospective observational cohort study recruited patients over 18 years with advanced cancer. The following were assessed: clinician-predicted survival (CPS), Eastern Cooperative Oncology Group performance status (ECOG-PS), patient reported outcome measures (anorexia, cognitive impairment, dyspnea, global health), metastatic disease, weight loss, modified Glasgow Prognostic Score (mGPS) based on C-reactive protein and albumin, lactate dehydrogenase (LDH), and white (WCC), neutrophil (NC), and lymphocyte cell counts. Survival at 1 and 3 months was assessed using area under the receiver operating curve and logistic regression analysis.Data were available on 478 patients, and the median survival was 4.27 (1.86-7.03) months. On univariate analysis, the following factors predicted death at 1 and 3 months: CPS, ECOG-PS, mGPS, WCC, NC (all p < .001), dyspnea, global health (both p ≤ .001), cognitive impairment, anorexia, LDH (all p < .01), and weight loss (p < .05). On multivariate analysis ECOG-PS, mGPS, and NC were independent predictors of survival at 1 and 3 months (all p < .01).The simple combination of ECOG-PS and mGPS is an important novel prognostic framework which can alert clinicians to patients with good performance status who are at increased risk of having a higher symptom burden and dying at 3 months. From the recent literature it is likely that this framework will also be useful in referral for early palliative care with 6-24 months survival.This large cohort study examined all validated prognostic factors in a head-to-head comparison and demonstrated the superior prognostic value of the Eastern Cooperative Oncology Group performance status (ECOG-PS)/modified Glasgow Prognostic Score (mGPS) combination over other prognostic factors. This combination is simple, accurate, and also relates to quality of life. It may be useful in identifying patients who may benefit from early referral to palliative care. It is proposed ECOG-PS/mGPS as the new prognostic domain in patients with advanced cancer." @default.
• W2938854921 created "2019-04-25" @default.
• W2938854921 creator A5002069421 @default.
• W2938854921 creator A5009522619 @default.
• W2938854921 creator A5010210639 @default.
• W2938854921 creator A5023963187 @default.
• W2938854921 creator A5035701998 @default.
• W2938854921 creator A5035786755 @default.
• W2938854921 creator A5043347769 @default.
• W2938854921 creator A5044101945 @default.
• W2938854921 creator A5057427289 @default.
• W2938854921 creator A5066805174 @default.
• W2938854921 creator A5079016899 @default.
• W2938854921 creator A5080732283 @default.
• W2938854921 date "2019-04-12" @default.
• W2938854921 modified "2023-10-18" @default.
• W2938854921 title "“How Long Have I Got?”—A Prospective Cohort Study Comparing Validated Prognostic Factors for Use in Patients with Advanced Cancer" @default.
• W2938854921 cites W1597830831 @default.
• W2938854921 cites W1745036040 @default.
• W2938854921 cites W1892212888 @default.
• W2938854921 cites W1988902102 @default.
• W2938854921 cites W2014229457 @default.
• W2938854921 cites W2017871729 @default.
• W2938854921 cites W2029199150 @default.
• W2938854921 cites W2041741066 @default.
• W2938854921 cites W2091553144 @default.
• W2938854921 cites W2096448257 @default.
• W2938854921 cites W2096756475 @default.
• W2938854921 cites W2103456976 @default.
• W2938854921 cites W2105299906 @default.
• W2938854921 cites W2115761859 @default.
• W2938854921 cites W2116976533 @default.
• W2938854921 cites W2121911732 @default.
• W2938854921 cites W2131193892 @default.
• W2938854921 cites W2147306113 @default.
• W2938854921 cites W2167571044 @default.
• W2938854921 cites W2177925826 @default.
• W2938854921 cites W2323133272 @default.
• W2938854921 cites W2406910612 @default.
• W2938854921 cites W2466228288 @default.
• W2938854921 cites W2466710561 @default.
• W2938854921 cites W2568702864 @default.
• W2938854921 cites W2602908601 @default.
• W2938854921 cites W2622673456 @default.
• W2938854921 cites W2748400555 @default.
• W2938854921 cites W2896015079 @default.
• W2938854921 cites W3175417087 @default.
• W2938854921 cites W4243801042 @default.
• W2938854921 doi "https://doi.org/10.1634/theoncologist.2018-0474" @default.
• W2938854921 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6738290" @default.
• W2938854921 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30975922" @default.
• W2938854921 hasPublicationYear "2019" @default.
• W2938854921 type Work @default.
• W2938854921 sameAs 2938854921 @default.
• W2938854921 citedByCount "21" @default.
• W2938854921 countsByYear W29388549212019 @default.
• W2938854921 countsByYear W29388549212020 @default.
• W2938854921 countsByYear W29388549212021 @default.
• W2938854921 countsByYear W29388549212022 @default.
• W2938854921 countsByYear W29388549212023 @default.
• W2938854921 crossrefType "journal-article" @default.
• W2938854921 hasAuthorship W2938854921A5002069421 @default.
• W2938854921 hasAuthorship W2938854921A5009522619 @default.
• W2938854921 hasAuthorship W2938854921A5010210639 @default.
• W2938854921 hasAuthorship W2938854921A5023963187 @default.
• W2938854921 hasAuthorship W2938854921A5035701998 @default.
• W2938854921 hasAuthorship W2938854921A5035786755 @default.
• W2938854921 hasAuthorship W2938854921A5043347769 @default.
• W2938854921 hasAuthorship W2938854921A5044101945 @default.
• W2938854921 hasAuthorship W2938854921A5057427289 @default.
• W2938854921 hasAuthorship W2938854921A5066805174 @default.
• W2938854921 hasAuthorship W2938854921A5079016899 @default.
• W2938854921 hasAuthorship W2938854921A5080732283 @default.
• W2938854921 hasBestOaLocation W29388549211 @default.
• W2938854921 hasConcept C121608353 @default.
• W2938854921 hasConcept C126322002 @default.
• W2938854921 hasConcept C143998085 @default.
• W2938854921 hasConcept C144301174 @default.
• W2938854921 hasConcept C151956035 @default.
• W2938854921 hasConcept C188816634 @default.
• W2938854921 hasConcept C2776907518 @default.
• W2938854921 hasConcept C2778654693 @default.
• W2938854921 hasConcept C38180746 @default.
• W2938854921 hasConcept C511355011 @default.
• W2938854921 hasConcept C544821477 @default.
• W2938854921 hasConcept C71924100 @default.
• W2938854921 hasConcept C72563966 @default.
• W2938854921 hasConceptScore W2938854921C121608353 @default.
• W2938854921 hasConceptScore W2938854921C126322002 @default.
• W2938854921 hasConceptScore W2938854921C143998085 @default.
• W2938854921 hasConceptScore W2938854921C144301174 @default.
• W2938854921 hasConceptScore W2938854921C151956035 @default.
• W2938854921 hasConceptScore W2938854921C188816634 @default.
• W2938854921 hasConceptScore W2938854921C2776907518 @default.
• W2938854921 hasConceptScore W2938854921C2778654693 @default.
• W2938854921 hasConceptScore W2938854921C38180746 @default.
• W2938854921 hasConceptScore W2938854921C511355011 @default.
• W2938854921 hasConceptScore W2938854921C544821477 @default.

• next